EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empiric antibiotic regimen for febrile neutropenia in cancer patients: a tertiary oncology center experience

Hasan Arafat, Marah Sabateen, Dana Sadaqa, Hammam Rjoup, Ayman Shoeibat, Musa Hindiyeh, Ali Sabateen

Frontiers in Oncology · 29.07.2026 · 16

DOI: 10.3389/fonc.2026.1876292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 29.07.2026. Verfasst von Hasan Arafat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Augusta Victoria Hospital, East Jerusalem, Palestine. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neutropenia is a major obstacle in the care of cancer patients. It is common in patients receiving chemotherapy, associated with significant morbidity and mortality, it occurs in 5-30% among patients with solid tumors and exceeds 80% of those undergoing chemotherapy for hematologic malignancies.

Objectives

This study primary endpoint was to assess the clinical outcome of the different antibiotic regimens. The secondary endpoint was to assess the microbiological appropriateness of antibiotic coverage of our carbapenem-sparing empiric regimen for neutropenic fever in patients admitted to the hemato-oncology departments to Augusta Victoria Hospital.

Methods

Patients data were extracted from the hospital health information system for all entries pertaining to neutropenic fever from 1 January 2022 to 30 November 2025. Statistical comparison between empiric antibiotic regimens was not performed because treatment escalation followed a predefined sequential protocol, resulting in non-independent groups. Assessment of antimicrobial appropriateness was completed using IBM SPSS Statistics via Fisher’s Exact Test. Patient data analyzed, included antibiotic classes used, bacterial culture results, antimicrobial sensitivity testing, cause of fever and outcome of antimicrobial treatment. Exclusions criteria included prophylaxis prescriptions for neutropenic fever and pediatric patients.

Results

Overall, 208 patients with febrile neutropenia were evaluated between January 1st, 2022, to November, 2025 th 2025. Hematology patients represented a major proportion compared to oncology (56.70% and 43.30%, respectively). Our institutional protocol, represented by ceftazidime and amikacin (the last is replaced with ciprofloxacin for patients with renal failure) was the most prescribed regimen (78.1%), followed by piperacillin-tazobactam ± vancomycin (16.4%) and finally meropenem (5.5%). Our institutional regimen was theoretically appropriate in 44.4% of cases, compared to piperacillin-tazobactam ± vancomycin (55.6%) and meropenem (88.9%).

Conclusion

The institutional stepwise empiric antibiotic protocol demonstrated high overall clinical response rates in patients with febrile neutropenia, with most patients achieving improvement without requiring escalation beyond first-line therapy. Simulated microbiological assessment suggested increasing pathogen coverage with broader-spectrum regimens, although this should be interpreted cautiously given the limited number of positive culture isolates. These findings support the effectiveness of the current protocol while emphasizing the importance of balancing microbiological coverage with antimicrobial stewardship principles.

Schlagwörter

Stichwörter der Autor:innen

antibiotic stewardshipfeverimmunocompromisedmalignancyneutropenic fever

Autor:innen und Institutionen

  • Department of Internal Medicine, Augusta Victoria Hospital, East Jerusalem, Palestine.
  • Department of Obstetrics and Gynecology, Holy Family Hospital, Bethlehem, Palestine.
  • Infectious Disease Unit, Augusta Victoria Hospital, East Jerusalem, Palestine.
  • Department of Laboratory Medicine, Augusta Victoria Hospital, East Jerusalem, Palestine.

Zitieren

APA

Arafat, H., Sabateen, M., Sadaqa, D., Rjoup, H., Shoeibat, A., Hindiyeh, M., & Sabateen, A. (2026). Empiric antibiotic regimen for febrile neutropenia in cancer patients: a tertiary oncology center experience. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1876292

Vancouver

Arafat H, Sabateen M, Sadaqa D, Rjoup H, Shoeibat A, Hindiyeh M, et al. Empiric antibiotic regimen for febrile neutropenia in cancer patients: a tertiary oncology center experience. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1876292

BibTeX
@article{Arafat2026,
  author = {Arafat, Hasan and Sabateen, Marah and Sadaqa, Dana and Rjoup, Hammam and Shoeibat, Ayman and Hindiyeh, Musa and Sabateen, Ali},
  title = {Empiric antibiotic regimen for febrile neutropenia in cancer patients: a tertiary oncology center experience},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1876292}
}
Kostenlos starten →